COP vs PFE: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-08.
ConocoPhillips · Energy
$108.44
-21.6% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
COP trades at a lower forward P/E
(18.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
PFE |
| Current Price |
$108.44 |
$25.22 |
| Fair Value Estimate |
$85.04 |
$25.92 |
| Upside to Fair Value |
-21.6%
|
+2.8%
|
| Market Cap |
$132.1B |
$143.7B |
| Forward P/E |
18.4x
|
19.2x
|
| EV / EBITDA |
6.1x
|
12.3x
|
| Price / Sales |
2.3x
|
2.3x
|
| Price / FCF |
8.6x
|
15.2x
|
| Revenue Growth YoY |
-2.5%
|
+5.4%
|
| Gross Margin |
29.2%
|
69.3%
|
| Operating Margin |
18.3%
|
23.4%
|
| Return on Equity |
11.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.64%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
ConocoPhillips is a major player in the Energy sector focused on Oil & Gas Exploration & Production. The company demonstrates medium business quality with a stable competitive position but faces earnings pressure as reflected in a 23.4% decline in earnings and a 2.5% decline in revenue in the most recent quarter year-over-year. Despite a solid ROE of 11.3% and attractive margins (gross margin 29.…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
COP |
PFE |
| Zone Low |
$63.78 |
$19.44 |
| Zone High |
$72.28 |
$22.03 |
| In Buy Zone? |
No
|
No
|